ArticleCureus2025
A Rare Case of a Dual-Mechanism-Based Thrombocytopenia Secondary to Carbamazepine in an Epileptic Patient.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Among antiepileptic drugs, carbamazepine often causes various hematological complications, one of which is thrombocytopenia. Reports of immune-mediated and myelosuppressive pathways being involved separately are common, but cases in which both occur together, known as dual-mechanism thrombocytopenia, are not very common. This case described a 35-year-old lady who had epilepsy and presented with unexplained bleeding and a notable decline in the level of her platelets. A high platelet count was found in the peripheral blood, and fewer megakaryocytes were seen in the bone marrow, indicating destruction of platelets in the bloodstream as well as underproduction in the bone marrow. Once carbamazepine was stopped, healthy blood counts came back quickly, indicating a certain connection. It demonstrated that monitoring platelets is important for those on carbamazepine therapy for a long time and that a dual cause should be considered for unexplained or severe low platelet counts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.